Results 171 to 180 of about 6,391 (198)
Some of the next articles are maybe not open access.

Pathobiology of acute lymphoblastic leukemia

Seminars in Diagnostic Pathology, 2011
In the present review, the authors described the pathobiological features of B- and T-ALL, which appear to be quite heterogeneous with regard to molecular pathogenesis. The last edition of the World Health Organization Classification considered this aspect by defining many entities based on genetic findings.
PAOLINI, STEFANIA   +5 more
openaire   +3 more sources

Acute Lymphoblastic Leukemia

Pediatric Clinics of North America, 1980
The improved outlook in childhood leukemia can be attributed to more accurate diagnosis, better supportive care, the use of drug combinations to achieve and maintain remission, and prophylactic therapy to prevent central nervous system leukemia. With the best treatment available today, 65 to 70 per cent of children are in complete continuous remission ...
openaire   +2 more sources

Leukemia cutis in acute lymphoblastic leukemia

Journal of the American Academy of Dermatology, 1994
separating normal epidermis from a diffuse dermal infiltrate of lymphoid blast cells with round and regular nuclei, inconspicuous nucleoli, and scanty, moderately basophilic cytoplasm. Immunophenotype analysis revealed strong positivity for CD 10.The patient wastreated with methotrexate, teniposide, cytosine arabinoside, and local irradiation, and a ...
J.M. Forjaz de Lacerda   +5 more
openaire   +3 more sources

Treatment of Acute Lymphoblastic Leukemia

Annual Review of Medicine, 1972
The treatment of acute lymphoblastic leukemia in the last decade can be said to have reached a revolutionary phase. Prior to that time, the disease was considered to be uniformly fatal and treatment was being given essen­ tially for palliation. These concepts have changed and now the well-informed investigator is employing acute leukemia protocols ...
Joseph H. Burchenal   +2 more
openaire   +3 more sources

Acute Lymphoblastic Leukemia

Hematology/Oncology Clinics of North America, 2009
Acute lymphoblastic leukemia and lymphoblastic lymphoma constitute a family of genetically heterogeneous lymphoid neoplasms derived from B- and T-lymphoid progenitors. Diagnosis is based on morphologic, immunophenotypic, and genetic features that allow differentiation from normal progenitors and other hematopoietic and nonhematopoietic neoplasms ...
openaire   +2 more sources

Acute lymphoblastic leukemia in the elderly

European Journal of Haematology, 1990
We report our findings in 18 patients with acute lymphoblastic leukemia (ALL) aged 60 years or older. A preleukemic syndrome was observed in 2 patients. Compared to younger adults with ALL, L3 morphology was unexpectedly frequent (4/16) T‐ALL was not observed. Other criteria of poor prognosis (high white blood cell count, CNS involvement, organomegaly,
Delannoy, André   +7 more
openaire   +3 more sources

Childhood acute lymphoblastic leukemia

Reviews in Clinical and Experimental Hematology, 2002
As cure rates in childhood acute lymphoblastic leukemia reach 80%, emphasis is increasingly placed on the accurate identification of drug‐resistant cases, the elucidation of the mechanisms involved in drug resistance and the development of new therapeutic strategies targeted toward the pivotal molecular lesions.
Mary V. Relling   +3 more
openaire   +3 more sources

Childhood Acute Lymphoblastic Leukemia

Pediatric Annals, 1988
Acute lymphoblastic leukemia accounts for 80% of leukemia in children. The exact cause is unknown, but some genetic, immunologic, viral, and environmental factors have been implicated. Symptoms at the time of diagnosis frequently include fever, bleeding, fatigue, and irritability. Initial white blood cell count and patient age at diagnosis are the most
Carol Diamond, Katherine K Matthay
openaire   +3 more sources

Asparaginase in Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma and Leukemia, 2014
Cure rates in pediatric acute lymphoblastic leukemia have significantly improved over the past decades. Now, almost 90% of children will survive the disease. The cure rates in adolescents, young adults, and adults have not kept pace with the improvements in younger patients, even though almost an equal proportion of adult patients achieve complete ...
Michael Rytting, Jitesh D. Kawedia
openaire   +3 more sources

Pharmacogenomics in acute lymphoblastic leukemia

Best Practice & Research Clinical Haematology, 2017
Pharmacogenomics is a fast-growing field of personalized medicine using a patient's genomic profile to determine drug disposition or response to drug therapy, in order to develop safer and more effective pharmacotherapy. Childhood acute lymphoblastic leukemia (ALL), being the most common malignancy in childhood, which is treated with uniform and ...
Shawn H.R. Lee, Jun J. Yang
openaire   +2 more sources

Home - About - Disclaimer - Privacy